571 related articles for article (PubMed ID: 25368234)
21. Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference.
Li WT; Zhou GY; Song XR; Chi WL; Ren RM; Wang XW
Neoplasma; 2005; 52(3):219-24. PubMed ID: 15875083
[TBL] [Abstract][Full Text] [Related]
22. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
[TBL] [Abstract][Full Text] [Related]
23. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
Ishii M; Iwahana M; Mitsui I; Minami M; Imagawa S; Tohgo A; Ejima A
Anticancer Drugs; 2000 Jun; 11(5):353-62. PubMed ID: 10912951
[TBL] [Abstract][Full Text] [Related]
24. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.
Kawabata S; Oka M; Shiozawa K; Tsukamoto K; Nakatomi K; Soda H; Fukuda M; Ikegami Y; Sugahara K; Yamada Y; Kamihira S; Doyle LA; Ross DD; Kohno S
Biochem Biophys Res Commun; 2001 Feb; 280(5):1216-23. PubMed ID: 11162657
[TBL] [Abstract][Full Text] [Related]
25. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
Rajendra R; Gounder MK; Saleem A; Schellens JH; Ross DD; Bates SE; Sinko P; Rubin EH
Cancer Res; 2003 Jun; 63(12):3228-33. PubMed ID: 12810652
[TBL] [Abstract][Full Text] [Related]
26. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
[TBL] [Abstract][Full Text] [Related]
27. Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer.
Chen Y; Bieber MM; Teng NN
Mol Carcinog; 2014 Aug; 53(8):625-34. PubMed ID: 23423781
[TBL] [Abstract][Full Text] [Related]
28. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ
Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965
[TBL] [Abstract][Full Text] [Related]
29. Preliminary study of the effects of β-elemene on MCF-7/ADM breast cancer stem cells.
Dong Y; Li L; Wang L; Zhou T; Liu JW; Gao YJ
Genet Mol Res; 2015 Mar; 14(1):2347-55. PubMed ID: 25867381
[TBL] [Abstract][Full Text] [Related]
30. Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference.
Li H; Zhou S; Li T; Liu Z; Wu J; Zeng G; Liu C; Gong J
Hepatogastroenterology; 2012 Oct; 59(119):2238-42. PubMed ID: 23435138
[TBL] [Abstract][Full Text] [Related]
31. Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride.
Takara K; Kitada N; Yoshikawa E; Yamamoto K; Horibe S; Sakaeda T; Nishiguchi K; Ohnishi N; Yokoyama T
Cancer Lett; 2009 Jun; 278(1):88-96. PubMed ID: 19201079
[TBL] [Abstract][Full Text] [Related]
32. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
[TBL] [Abstract][Full Text] [Related]
33. Unexpected Lower Expression of Oncoprotein Gankyrin in Drug Resistant ABCG2 Overexpressing Breast Cancer Cell Lines.
Taheri T; Jamialahmadi K; Khadijeh F
Asian Pac J Cancer Prev; 2017 Dec; 18(12):3413-3418. PubMed ID: 29286612
[TBL] [Abstract][Full Text] [Related]
34. Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2.
Kowalski P; Wichert A; Holm PS; Dietel M; Lage H
Cancer Gene Ther; 2001 Mar; 8(3):185-92. PubMed ID: 11332989
[TBL] [Abstract][Full Text] [Related]
35. Multidrug resistance in breast cancer cells during epithelial-mesenchymal transition is modulated by breast cancer resistant protein.
Chen WJ; Wang H; Tang Y; Liu CL; Li HL; Li WT
Chin J Cancer; 2010 Feb; 29(2):151-7. PubMed ID: 20109342
[TBL] [Abstract][Full Text] [Related]
36. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.
Yoshikawa M; Ikegami Y; Hayasaka S; Ishii K; Ito A; Sano K; Suzuki T; Togawa T; Yoshida H; Soda H; Oka M; Kohno S; Sawada S; Ishikawa T; Tanabe S
Int J Cancer; 2004 Jul; 110(6):921-7. PubMed ID: 15170677
[TBL] [Abstract][Full Text] [Related]
37. Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells.
Ishikawa T; Ikegami Y; Sano K; Nakagawa H; Sawada S
Curr Pharm Des; 2006; 12(3):313-25. PubMed ID: 16454746
[TBL] [Abstract][Full Text] [Related]
38. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
39. Reversal of BCRP-mediated multidrug resistance by stable expression of small interfering RNAs.
Lv H; He Z; Liu X; Yuan J; Yu Y; Chen Z
J Cell Biochem; 2007 Sep; 102(1):75-81. PubMed ID: 17372930
[TBL] [Abstract][Full Text] [Related]
40. The effect of siRNA-Egr-1 and camptothecin on growth and chemosensitivity of breast cancer cell lines.
Parra E; Ferreira J
Oncol Rep; 2010 Apr; 23(4):1159-65. PubMed ID: 20204305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
